C Ray Therapeutics Highlights Supply-Chain Push for Actinium-225 and Radiopharma Scale-Up

According to a recent LinkedIn post from C Ray Therapeutics, the company is highlighting NorthStar Medical Radioisotopes’ role in addressing supply constraints for Actinium‑225, a key isotope in targeted alpha therapy. The post describes how limited Ac‑225 availability has created a “valuation valley” between strong clinical data and commercially viable production.

The LinkedIn post indicates that NorthStar will present at XDC Conference 2026 in Chengdu on securing and scaling the global Ac‑225 supply chain. It emphasizes NorthStar’s model of co-locating commercial‑scale radioisotope production and radiopharmaceutical CDMO services on a single U.S. campus to minimize decay losses and logistics risk.

According to the post, NorthStar’s infrastructure is positioned as already proven at scale through strategic agreements spanning preclinical to late‑stage radioantibody programs. The post also notes NorthStar’s multi‑isotope capabilities, including Cu‑67 for theranostic applications that pair imaging and therapy, which may broaden addressable program types.

As shared in the post, C Ray Therapeutics is co-organizing the International RDC Sub‑Forum at XDC 2026 and characterizes itself as a strategic bridge between NorthStar’s U.S. isotope infrastructure and radiopharma manufacturing in Asia. The collaboration focus appears to be on creating a seamless supply‑to‑CDMO chain from NorthStar’s Beloit campus to formulation suites in Chengdu, with the aim of reducing “decay tax” at each handoff.

For investors, the post suggests that ecosystem‑level coordination around Ac‑225 and Cu‑67 supply could de‑risk late‑stage radiopharmaceutical development and accelerate time to market for alpha therapies. If C Ray succeeds in anchoring itself as a central connector between U.S. isotope producers and Asian manufacturing, it could enhance its strategic relevance in the radiopharmaceutical value chain and potentially support future partnership and revenue opportunities.

The emphasis on solving supply chain infrastructure rather than scientific uncertainty may signal a shift toward industrialization in targeted alpha therapy, with implications for scale-up investment and competitive positioning. Reliable access to Ac‑225 and complementary isotopes could become a differentiator for radiopharma developers, and C Ray’s facilitation role at XDC 2026 may offer visibility into emerging collaborations and capacity build-out across regions.